ArticleJAMA oncology2019

Changes to Model Assumptions of the Cost-effectiveness of Durvalumab Therapy for Non-Small Cell Lung Cancer.

Smith Giri et al.PubMed ↗Publisher ↗

No numbers read from the abstract.